Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity

Journal of the National Cancer Institute

Volumn 105, Issue 18, 2013, Pages 1344-1354

  Schmitz, Kathryn H ^a   Neuhouser, Marian L ^b   Agurs Collins, Tanya ^c   Zanetti, Krista A ^c   Cadmus Bertram, Lisa ^d   Dean, Lorraine T ^a   Drake, Bettina F ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; GOSERELIN; PLACEBO; PLATINUM DERIVATIVE; RALOXIFENE; TAMOXIFEN; TAXANE DERIVATIVE; VINCA ALKALOID; ZOLEDRONIC ACID;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOTOXICITY; COMORBIDITY; CONCEPTUAL FRAMEWORK; DISEASE FREE SURVIVAL; DRUG EFFICACY; ETHNIC AND RACIAL GROUPS; ETHNICITY; FATIGUE; FEEDBACK SYSTEM; FUNCTIONAL STATUS; HUMAN; LYMPHEDEMA; MEDICAL RESEARCH; MORTALITY; OBESITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RACE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT;

BODY MASS INDEX; BREAST NEOPLASMS; COMORBIDITY; CONTINENTAL POPULATION GROUPS; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; FATIGUE; HEALTH STATUS; HUMANS; LYMPHEDEMA; NEOPLASMS; OBESITY; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84886916146     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt223     Document Type: Review

References (138)

1. National Center For Health Statistics. Prevalence of Overweight, Obesity and Extreme Obesity Among Adults: United States, Trends 1976-80 Through 2005-2006. Hyattsville, MD: National Center for Health Statistics; 2008.
2. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5): 491-497.
3. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung H-C. Deaths: Final Data for 2009. Hyattsville, MD: National Center for Health Statistics; 2012.
4. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9): 2338-2366.
5. Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25(18): 2522-2527.
6. Griggs JJ, Culakova E, Sorbero ME, et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol. 2007;25(3): 277-284.
7. Calle R, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl J Med. 2003;348(17): 1625-1638.
8. Chamberlain C, Romundstad P, Vatten L, et al. The association of weight gain during adulthood with prostate cancer incidence and survival: a population- based cohort. Int J Cancer. 2011;129(5): 1199-1206.
9. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4): 675-684.
10. Joshu CE, Mondul AM, Menke A, et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila). 2011;4(4): 544-551.
11. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4): 486-501.
12. Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 2010;126(3): 692-702.
13. Kwan ML, Chen WY, Kroenke CH, et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat. 2012;132(2): 729-39.
14. Cecchini R, Costantino J, Cauley J, et al. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP-P1 and STAR Breast Cancer Prevention Trials. Cancer Prev Res (Phila). 2012;5(4): 583-592.
15. Oxentenko AS, Bardia A, Vierkant RA, et al. Body size and incident colorectal cancer: a prospective study of older women. Cancer Prev Res (Phila). 2010;3(12): 1608-1620.
16. Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr. 2012;32: 311-342.
17. Yang HS, Yoon C, Myung SK, et al. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2011;21(9): 1525-1532.
18. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5(7): 901-910.
19. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3): 627-635.
20. Williams SB, Salami S, Regan MM, et al. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. Cancer. 2012;118(10): 2651-2658.
21. World Cancer Research Fund/AICR. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR; 2007.
22. Prizment AE, Flood A, Anderson KE, et al. Survival of women with colon cancer in relation to precancer anthropometric characteristics: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2010;19(9): 2229-2237.
23. Sinicrope FA, Foster NR, Sargent DJ, et al. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16(6): 93.
24. Bessonova L, Marshall SF, Ziogas A, et al. The association of body mass index with mortality in the California Teachers Study. Int J Cancer. 2011;129(10): 2492-2501.
25. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29(1): 25-31.
26. Conroy SM, Maskarinec G, Wilkens LR, et al. Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat. 2011;129(2): 565-574.
27. Nichols HB, Trentham-Dietz A, Egan KM, et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 2009;18(5): 1403-1409.
28. Caan BJ, Kwan ML, Hartzell G, et al. Pre-diagnosis body mass index, postdiagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control. 2008;19(10): 1319-1328.
29. McCawley GM, Ferriss JS, Geffel D, et al. Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg. 2009;208(6): 1093-1098.
30. Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring). 2009;17(4): 796-802.
31. Ashrafian H, Ahmed K, Rowland SP, et al. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011;117(9): 1788-1799.
32. Sainsbury A, Goodlad RA, Perry SL, et al. Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev. 2008;17(6): 1401-1410.
33. Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7): 653-662.
34. Thivat E, Therondel S, Lapirot O, et al. Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer. 2010;10: 648.
35. Caan BJ KM, Shu XO, Pierce JP, et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epi Bio Prev. 2012;21(8): 1260-1271.
36. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9): 630-643.
37. Villasenor A, Ballard-Barbash R, Baumgartner K, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012;6(4): 398-406.
38. Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 Trial. J Clin Oncol. 2011;29(19): 2653-2659.
39. de Azambuja E, McCaskill-Stevens W, Francis P, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 2010;119(1): 145-153.
40. Johansson H, Gandini S, Guerrieri-Gonzaga A, et al. Effect of fenretinide and low-dose tamoxifen on inuslin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008;68(22): 9512-9518.
41. Le TT, Huff TB, Cheng JX. Coherent anti-Stokes Raman scattering imaging of lipids in cancer metastasis. BMC Cancer 2009;9: 42.
42. Hellawell GO, Turner GD, Davies DR, et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002;62(10): 2942-2950.
43. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 2007;13(12): 3611-3616.
44. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13): 1553-1561.
45. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11(12): 886-895.
46. Griggs JJ, Sorbero ME, Stark AT, et al. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81(1): 21-31.
47. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11): 1267-1273.
48. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24): 4524-4531.
49. Smith K, Wray L, Klein-Cabral M, et al. Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clin Breast Cancer. 2005;6(3): 260-266; discussion 267-269.
50. Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst. 2003;95(20): 1545-1548.
51. Whitmer RA, Gunderson EP, Barrett-Connor E, et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330(7504): 1360.
52. Benoist S, Panis Y, Alves A, et al. Impact of obesity on surgical outcomes after colorectal resection. Am J Surg. 2000;179(4): 275-281.
53. Eichenberger A, Proietti S, Wicky S, et al. Morbid obesity and postoperative pulmonary atelectasis: an underestimated problem. Anesth Analg. 2002;95(6): 1788-1792.
54. Choban PS, Flancbaum L. The impact of obesity on surgical outcomes: a review. J Am Coll Surg. 1997;185(6): 593-603.
55. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9: 88.
56. Koenig SM. Pulmonary complications of obesity. Am J Med Sci. 2001;321(4): 249-279.
57. Munkhaugen J, Lydersen S, Wideroe TE, et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis. 2009;54(4): 638-646.
58. Cronin DP, Harlan LC, Potosky AL, et al. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006;101(10): 2308-2318.
59. Cronin DP, Harlan LC, Clegg LX, et al. Patterns of care in a populationbased random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol. 2005;23(2): 73-81.
60. Harlan LC, Klabunde CN, Ambs AH, et al. Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv. 2009;3(2): 89-98.
61. Gross CP, McAvay GJ, Guo Z, et al. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109(12): 2410-2419.
62. Honnor A. Classification, aetiology and nursing management of lymphoedema. Br J Nurs. 2008;17(9): 576-586.
63. Ahmed RL, Schmitz KH, Prizment AE, et al. Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study. Breast Cancer Res Treat. 2011;130(3): 981-991.
64. Meeske KA, Sullivan-Halley J, Smith AW, et al. Risk factors for arm lymphedema following breast cancer diagnosis in black women and white women. Breast Cancer Res Treat. 2009;113(2): 383-391.
65. Helyer LK, Varnic M, Le LW, et al. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010;16(1): 48-54.
66. Ridner SH, Dietrich MS, Stewart BR, et al. Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer. 2011;19(6): 853-857.
67. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. QJM. 2005;98(5): 343-348.
68. Mak SS, Yeo W, Lee YM, et al. Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res. 2008;57(6): 416-425.
69. Shaw C, Mortimer P, Judd PA. A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema. Cancer. 2007;110(8): 1868-1874.
70. Beesley V, Janda M, Eakin E, et al. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer. 2007;109(12): 2607-2614.
71. Kim JH, Choi JH, Ki EY, et al. Incidence and risk factors of lower-extremity lymphedema after radical surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage IIA cervical cancer. Int J Gynecol Cancer. 2012;22(4): 686-691.
72. Ohba Y, Todo Y, Kobayashi N, et al. Risk factors for lower-limb lymphedema after surgery for cervical cancer. Int J Clin Oncol. 2011;16(3): 238-243.
73. Kizer NT, Thaker PH, Gao F, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011;117(5): 948-956.
74. Todo Y, Yamamoto R, Minobe S, et al. Risk factors for postoperative lowerextremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol. 2010;119(1): 60-64.
75. Valdivieso M, Kujawa AM, Jones T, et al. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci. 2012;9(2): 163-73.
76. Fader AN, Frasure HE, Gil KM, et al. Quality of life in endometrial cancer survivors: what does obesity have to do with it? Obstet Gynecol Int. 2011;2011: 308609.
77. Courneya KS, Karvinen KH, Campbell KL, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol. 2005;97(2): 422-430.
78. Milne HM, Gordon S, Guilfoyle A, et al. Association between physical activity and quality of life among Western Australian breast cancer survivors. Psychooncology. 2007;16(12): 1059-1068.
79. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12): 1250-1261.
80. Dieperink KB, Hansen S, Wagner L, et al. Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. Acta Oncol. 2012;51(6): 722-729.
81. Anast JW, Sadetsky N, Pasta DJ, et al. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005;173(4): 1132-1138.
82. Jansen L, Koch L, Brenner H, et al. Quality of life among long-term (≥5 years) colorectal cancer survivors - systematic review. Eur J Cancer. 2010;46(16): 2879-2888.
83. Mosher CE, Sloane R, Morey MC, et al. Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors. Cancer. 2009;115(17): 4001-4009.
84. Blanchard CM, Stein K, Courneya KS. Body mass index, physical activity, and health-related quality of life in cancer survivors. Med Sci Sports Exerc. 2010;42(4): 665-671.
85. Wolin KY, Luly J, Sutcliffe S, et al. Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol. 2010;183(2): 629-633.
86. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol. 2000;37(4 Suppl 6): 14-17.
87. Lawrence DP, Kupelnick B, Miller K, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32: 40-50.
88. Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. Cancer. 2012;118(8 Suppl): 2261-2269.
89. Andrykowski MA, Donovan KA, Laronga C, et al. Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer. 2010;116(24): 5740-5748.
90. Reinertsen KV, Cvancarova M, Loge JH, et al. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv. 2010;4(4): 405-414.
91. Gerber LH, Stout N, McGarvey C, et al. Factors predicting clinically significant fatigue in women following treatment for primary breast cancer. Support Care Cancer. 2011;19(10): 1581-1591.
92. Winters-Stone KM, Bennett JA, Nail L, et al. Strength, physical activity, and age predict fatigue in older breast cancer survivors. Oncol Nurs Forum. 2008;35(5): 815-821.
93. Basen-Engquist K, Scruggs S, Jhingran A, et al. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009;200(3): 288.e1-288.e8.
94. Meeske KA, Siegel SE, Globe DR, et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol. 2005;23(24): 5501-5510.
95. Meeske K, Smith AW, Alfano CM, et al. Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. Qual Life Res. 2007;16(6): 947-960.
96. Stubblefield MD, McNeely ML, Alfano CM, et al. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer. 2012;118(8 Suppl): 2250-2260.
97. Schneider BP, Zhao F, Wang M, et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol. 2012;30(25): 3051-3057.
98. Speck RM, Sammel MD, Farrar JT, et al. Racial disparities in the incidence of dose-limiting chemotherapy induced peripheral neuropathy. In: San Antonio Breast Cancer Symposium; San Antonio, TX, December 4-8, 2012.
99. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1): 23-31.
100. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120(9): 1986-1992.
101. Ness KK, Wall MM, Oakes JM, et al. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. Ann Epidemiol. 2006;16(3): 197-205.
102. Sweeney C, Schmitz KH, Lazovich D, et al. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98(8): 521-529.
103. Michael Y, Kawachi I, Berkman L, et al. The persistent impact of breast carcinoma on functional health status: prospective evidence from the Nurses' Health Study. Cancer. 2000;89(11): 2176-2186.
104. Fontaine KR, Cheskin LJ, Barofsky I. Health-related quality of life in obese persons seeking treatment. J Fam Pract. 1996;43(3): 265-270.
105. Stewart AL, Brook RH. Effects of being overweight. Am J Public Health. 1983;73(2): 171-178.
106. Trakas K, Oh PI, Singh S, et al. The health status of obese individuals in Canada. Int J Obes Relat Metab Disord. 2001;25(5): 662-668.
107. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24): 2231-2247.
108. Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012;118(8 Suppl): 2277-2287.
109. Howlader NNA, Krapcho M, Neyman N, et al. eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/ csr/1975-2009-pops09/. Accessed April 1, 2012.
110. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
111. Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009;27(13): 2157-2162.
112. Mukhtar RA, Moore AP, Nseyo O, et al. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011;130(2): 635-644.
113. Sarker M, Jatoi I, Becher H. Racial differences in breast cancer survival in women under age 60. Breast Cancer Res Treat. 2007;106(1): 135-141.
114. Christiansen N, Chen L, Gilmore J, et al. Association between African American race and outcomes in patients with nonmetastatic triple-negative breast cancer: a retrospective analysis by using results from the Georgia Cancer Specialist Database. Clin Breast Cancer. 2012;12(4): 270-275.
115. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117(16): 3658-3669.
116. Dignam JJ, Wieand K, Johnson KA, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2006;97(3): 245-254.
117. Lu Y, Ma H, Malone KE, et al. Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol. 2011;29(25): 3358-3365.
118. Merkin SS, Stevenson L, Powe N. Geographic socioeconomic status, race, and advanced-stage breast cancer in New York City. Am J Public Health. 2002;92(1): 64-70.
119. Myers RE, Wolf TA, McKee L, et al. Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia. Cancer. 1996;78(3): 471-479.
120. Shen Y, Dong W, Esteva FJ, et al. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat. 2007;102(3): 347-356.
121. Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med. 2006;144(8): 541-553.
122. Gerend MA, Pai M. Social determinants of black-white disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev. 2008;17(11): 2913-2923.
123. Weinrich SP, Reynolds WA, Jr., Tingen MS, et al. Barriers to prostate cancer screening. Cancer Nurs. 2000;23(2): 117-121.
124. Kwan ML, Darbinian J, Schmitz KH, et al. Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010;145(11): 1055-1063.
125. Kocak Z, Overgaard J. Risk factors of arm lymphedema in breast cancer patients. Acta Oncol. 2000;39(3): 389-392.
126. Ashing-Giwa KT, Tejero JS, Kim J, et al. Examining predictive models of HRQOL in a population-based, multiethnic sample of women with breast carcinoma. Qual Life Res. 2007;16(3): 413-428.
127. Paskett ED, Alfano CM, Davidson MA, et al. Breast cancer survivors' health-related quality of life: racial differences and comparisons with noncancer controls. Cancer. 2008;113(11): 3222-3230.
128. Powe BD, Hamilton J, Hancock N, et al. Quality of life of African American cancer survivors. A review of the literature. Cancer. 2007;109(2 Suppl): 435-445.
129. Yanez B, Thompson EH, Stanton AL. Quality of life among Latina breast cancer patients: a systematic review of the literature. J Cancer Surviv. 2011;5(2): 191-207.
130. Bowen DJ, Alfano CM, McGregor BA, et al. Possible socioeconomic and ethnic disparities in quality of life in a cohort of breast cancer survivors. Breast Cancer Res Treat. 2007;106(1): 85-95.
131. Rao D, Debb S, Blitz D, et al. Racial/Ethnic differences in the healthrelated quality of life of cancer patients. J Pain Symptom Manage. 2008;36(5): 488-496.
132. Russell GV, Pierce CW, Nunley L. Financial implications of obesity. Orthop Clin North Am, 2011;42(1): 123-127, vii.
133. Ashing-Giwa KT, Padilla G, Tejero J, et al. Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors. Psychooncology. 2004;13(6): 408-428.
134. Gill KM, Mishel M, Belyea M, et al. Triggers of uncertainty about recurrence and long-term treatment side effects in older African American and Caucasian breast cancer survivors. Oncol Nurs Forum. 2004;31(3): 633-639.
135. Shelby RA, Lamdan RM, Siegel JE, et al. Standardized versus open-ended assessment of psychosocial and medical concerns among African American breast cancer patients. Psychooncology. 2006;15(5): 382-397.
136. Janz NK, Mujahid MS, Hawley ST, et al. Racial/ethnic differences in quality of life after diagnosis of breast cancer. J Cancer Surviv. 2009;3(4): 212-222.
137. Schneider BP, Li L, Miller K, et al. Genetic associations with taxaneinduced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol. 2011;29(15 Suppl):abstract 1000.
138. Paxton RJ, Phillips KL, Jones LA, et al. Associations among physical activity, body mass index, and health-related quality of life by race/ethnicity in a diverse sample of breast cancer survivors. Cancer. 2012;118(16): 4024-4031.